dc.contributor.author |
Aouad M.T. |
dc.contributor.author |
Siddik-Sayyid S.M. |
dc.contributor.author |
Taha S.K. |
dc.contributor.author |
Azar M.S. |
dc.contributor.author |
Nasr V.G. |
dc.contributor.author |
Hakki M.A. |
dc.contributor.author |
Zoorob D.G. |
dc.contributor.author |
Baraka A.S. |
dc.contributor.editor |
|
dc.date |
Feb-2007 |
dc.date.accessioned |
2017-10-05T15:29:23Z |
dc.date.available |
2017-10-05T15:29:23Z |
dc.date.issued |
2007 |
dc.identifier |
10.1017/S0265021506001323 |
dc.identifier.isbn |
|
dc.identifier.issn |
02650215 |
dc.identifier.uri |
http://hdl.handle.net/10938/15235 |
dc.description.abstract |
Background and objective: Ondansetron is widely used for the prophylaxis of postoperative nausea and vomiting, while haloperidol is an antiemetic that lacks recent data on efficacy and adverse effects. Methods: In this prospective, randomized, double-blinded study involving 93 females undergoing gynaecological procedures under general anaesthesia, we compared the efficacy and adverse effects of prophylactic haloperidol 1 mg intravenous and ondansetron 4 mg intravenous vs. placebo. Results: During the overall observation period (0-24 h), in the haloperidol, ondansetron and placebo groups respectively, the incidence of nausea and-or vomiting was 40.7percent (11-27), 48.2percent (13-27) and 55.5percent (15-27), and the need of rescue antiemetics was 22.2percent (6-27), 44.4percent (12-27) and 40.7percent (11-27), with P values 0.05 among the three groups. During the early observation period (0-2 h), in the haloperidol, ondansetron and placebo groups respectively, the incidence of nausea and-or vomiting was 13.7percent (4-29), 26.6percent (8-30) and 43percent (13-30), and the need for rescue antiemetics was 6.8percent (2-29), 26.6percent (8-30) and 36.6percent (11-30). Between haloperidol and placebo groups, the P value was 0.04 for nausea and-or vomiting, and was 0.01 for rescue antiemetics, in addition to lower nausea scores (P = 0.03). During the late observation period (2-24 h), no significant difference was shown among the three groups. Conclusion: The prophylactic administration of 1 mg intravenous haloperidol or 4 mg ondansetron, in female patients undergoing gynaecological surgery, did not improve the overall incidence of nausea and-or vomiting vs. placebo. However, haloperidol 1 mg proved to be an effective antiemetic in the early observation period without significant adverse effects. © 2006 Copyright European Society of Anaesthesiology. |
dc.format.extent |
|
dc.format.extent |
Pages: (171-178) |
dc.language |
English |
dc.publisher |
PHILADELPHIA |
dc.relation.ispartof |
Publication Name: European Journal of Anaesthesiology; Publication Year: 2007; Volume: 24; no. 2; Pages: (171-178); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
Haloperidol vs. ondansetron for the prevention of postoperative nausea and vomiting following gynaecological surgery |
dc.type |
Article |
dc.contributor.affiliation |
Aouad, M.T., American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon, Department of Anesthesiology, American University of Beirut Medical Center, P.O. Box 11 0236, Beirut, Lebanon |
dc.contributor.affiliation |
Siddik-Sayyid, S.M., American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon |
dc.contributor.affiliation |
Taha, S.K., American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon |
dc.contributor.affiliation |
Azar, M.S., American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon |
dc.contributor.affiliation |
Nasr, V.G., American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon |
dc.contributor.affiliation |
Hakki, M.A., American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon |
dc.contributor.affiliation |
Zoorob, D.G., American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon |
dc.contributor.affiliation |
Baraka, A.S., American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon |
dc.contributor.authorAddress |
Aouad, M.T.; Department of Anesthesiology, American University of Beirut Medical Center, P.O. Box 11 0236, Beirut, Lebanon; email: mm01@aub.edu.lb |
dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Anesthesiology; |
dc.contributor.authorDepartment |
Anesthesiology |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
mm01@aub.edu.lb |
dc.contributor.faculty |
Faculty of Medicine |
dc.contributor.authorInitials |
Aouad, MT |
dc.contributor.authorInitials |
Siddik-Sayyid, SM |
dc.contributor.authorInitials |
Taha, SK |
dc.contributor.authorInitials |
Azar, MS |
dc.contributor.authorInitials |
Nasr, VG |
dc.contributor.authorInitials |
Hakki, MA |
dc.contributor.authorInitials |
Zoorob, DG |
dc.contributor.authorInitials |
Baraka, AS |
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
Aouad, MT (reprint author), Amer Univ Beirut, Dept Anesthesiol, Med Ctr, POB 11, Beirut 0236, Lebanon. |
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut Medical Center |
dc.description.cited |
Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097-00000542-199909000-00022; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056-NEJMoa032196; Arcioni R, 2002, ANESTH ANALG, V94, P1553, DOI 10.1097-00000539-200206000-00033; BARON MD, 1975, ANESTHESIOLOGY, V42, P508; Buttner M, 2004, ANESTHESIOLOGY, V101, P1454; Charbit B, 2005, ANESTHESIOLOGY, V102, P1094, DOI 10.1097-00000542-200506000-00006; Critchley P, 2001, J PAIN SYMPTOM MANAG, V22, P631, DOI 10.1016-S0885-3924(01)00323-2; Diemunsch P, 2000, DRUGS, V60, P533, DOI 10.2165-00003495-200060030-00002; Diemunsch P, 1999, BRIT J ANAESTH, V82, P274; DYRBERG V, 1962, ACTA ANAESTH SCAND, V6, P37, DOI 10.1111-j.1399-6576.1962.tb00102.x; Eberhart LHJ, 2002, ANAESTHESIA, V57, P1022, DOI 10.1046-j.1365-2044.2002.02822.x; Fortney JT, 1998, ANESTH ANALG, V86, P731, DOI 10.1097-00000539-199804000-00011; Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213-01.ANE.0000068580.00245.95; Graczyk SG, 1997, ANESTH ANALG, V84, P325, DOI 10.1097-00000539-199702000-00015; Habib AS, 2005, J CLIN ANESTH, V17, P62, DOI 10.1016-j.jclinane.2004.04.004; Habib AS, 2003, ANESTH ANALG, V96, P1377; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001-jama.249.13.1743; Lawrence KR, 1997, PHARMACOTHERAPY, V17, P531; Melzack R, 1989, J Pain Symptom Manage, V4, P157, DOI 10.1016-0885-3924(89)90010-9; Parlow JL, 2004, ANESTH ANALG, V98, P1072, DOI 10.1213-01.ANE.0000105880.59649.5C; Perrault LP, 2000, CAN J ANAESTH, V47, P251; Scuderi PE, 2005, ANESTHESIOLOGY, V102, P1081, DOI 10.1097-00000542-200506000-00003; Sharma ND, 1998, AM J CARDIOL, V81, P238, DOI 10.1016-S0002-9149(97)00888-6; STATILE L, 1988, GEN PHARMACOL, V19, P451, DOI 10.1016-0306-3623(88)90046-8; Sun R, 1997, ANESTH ANALG, V84, P331, DOI 10.1097-00000539-199702000-00016; TAHA S, 2005, CAN J ANAESTH, V52, P349; TORNETTA FJ, 1972, ANESTH ANAL CURR RES, V51, P964; Tramer MR, 1997, ANESTHESIOLOGY, V87, P1277, DOI 10.1097-00000542-199712000-00004; White PF, 2005, ANESTHESIOLOGY, V102, P1101, DOI 10.1097-00000542-200506000-00007; White PF, 2002, ANESTH ANALG, V95, P789, DOI 10.1213-01.ANE.0000029880.86965.E1 |
dc.description.citedCount |
21 |
dc.description.citedTotWOSCount |
16 |
dc.description.citedWOSCount |
15 |
dc.format.extentCount |
8 |
dc.identifier.articleNo |
|
dc.identifier.coden |
EJANE |
dc.identifier.pubmedID |
16938159 |
dc.identifier.scopusID |
33846062061 |
dc.identifier.url |
|
dc.publisher.address |
530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
Eur. J. Anaesth. |
dc.relation.ispartOfIssue |
2 |
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
European Journal of Anaesthesiology |
dc.relation.ispartofPubTitleAbbr |
Eur. J. Anaesthesiol. |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
24 |
dc.source.ID |
WOS:000244155400011 |
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
Anaesthesia general, side-effects |
dc.subject.otherAuthKeyword |
Antiemetics, surgery gynaecological |
dc.subject.otherAuthKeyword |
Postoperative nausea and vomiting |
dc.subject.otherChemCAS |
cisatracurium, 96946-41-7, 96946-42-8 |
dc.subject.otherChemCAS |
droperidol, 548-73-2 |
dc.subject.otherChemCAS |
fentanyl, 437-38-7 |
dc.subject.otherChemCAS |
glycopyrronium bromide, 596-51-0 |
dc.subject.otherChemCAS |
haloperidol, 52-86-8 |
dc.subject.otherChemCAS |
isoflurane, 26675-46-7 |
dc.subject.otherChemCAS |
lidocaine, 137-58-6, 24847-67-4, 56934-02-2, 73-78-9 |
dc.subject.otherChemCAS |
neostigmine, 114-80-7, 588-17-0, 59-99-4, 8048-84-8 |
dc.subject.otherChemCAS |
nitrous oxide, 10024-97-2 |
dc.subject.otherChemCAS |
ondansetron, 103639-04-9, 116002-70-1, 99614-01-4 |
dc.subject.otherChemCAS |
paracetamol, 103-90-2 |
dc.subject.otherChemCAS |
promethazine, 58-33-3, 60-87-7 |
dc.subject.otherChemCAS |
propofol, 2078-54-8 |
dc.subject.otherChemCAS |
Antiemetics |
dc.subject.otherChemCAS |
Haloperidol, 52-86-8 |
dc.subject.otherChemCAS |
Ondansetron, 99614-02-5 |
dc.subject.otherIndex |
anesthetic agent |
dc.subject.otherIndex |
antiemetic agent |
dc.subject.otherIndex |
cisatracurium |
dc.subject.otherIndex |
droperidol |
dc.subject.otherIndex |
fentanyl |
dc.subject.otherIndex |
glycopyrronium bromide |
dc.subject.otherIndex |
haloperidol |
dc.subject.otherIndex |
isoflurane |
dc.subject.otherIndex |
lidocaine |
dc.subject.otherIndex |
neostigmine |
dc.subject.otherIndex |
neuromuscular blocking agent |
dc.subject.otherIndex |
nitrous oxide |
dc.subject.otherIndex |
ondansetron |
dc.subject.otherIndex |
paracetamol |
dc.subject.otherIndex |
placebo |
dc.subject.otherIndex |
promethazine |
dc.subject.otherIndex |
propofol |
dc.subject.otherIndex |
adult |
dc.subject.otherIndex |
anesthesia induction |
dc.subject.otherIndex |
article |
dc.subject.otherIndex |
clinical trial |
dc.subject.otherIndex |
controlled clinical trial |
dc.subject.otherIndex |
controlled study |
dc.subject.otherIndex |
double blind procedure |
dc.subject.otherIndex |
drug efficacy |
dc.subject.otherIndex |
drug induced headache |
dc.subject.otherIndex |
drug safety |
dc.subject.otherIndex |
female |
dc.subject.otherIndex |
general anesthesia |
dc.subject.otherIndex |
gynecologic surgery |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
major clinical study |
dc.subject.otherIndex |
postoperative nausea and vomiting |
dc.subject.otherIndex |
randomized controlled trial |
dc.subject.otherIndex |
scoring system |
dc.subject.otherIndex |
statistical significance |
dc.subject.otherIndex |
treatment outcome |
dc.subject.otherIndex |
unspecified side effect |
dc.subject.otherIndex |
Adult |
dc.subject.otherIndex |
Analysis of Variance |
dc.subject.otherIndex |
Anesthesia, General |
dc.subject.otherIndex |
Antiemetics |
dc.subject.otherIndex |
Double-Blind Method |
dc.subject.otherIndex |
Female |
dc.subject.otherIndex |
Gynecologic Surgical Procedures |
dc.subject.otherIndex |
Haloperidol |
dc.subject.otherIndex |
Humans |
dc.subject.otherIndex |
Injections, Intravenous |
dc.subject.otherIndex |
Middle Aged |
dc.subject.otherIndex |
Ondansetron |
dc.subject.otherIndex |
Postoperative Nausea and Vomiting |
dc.subject.otherIndex |
Prospective Studies |
dc.subject.otherIndex |
Risk Factors |
dc.subject.otherIndex |
Time Factors |
dc.subject.otherIndex |
Treatment Outcome |
dc.subject.otherKeywordPlus |
INTRAVENOUS-HALOPERIDOL |
dc.subject.otherKeywordPlus |
PATIENT SATISFACTION |
dc.subject.otherKeywordPlus |
ANTIEMETIC ACTIVITY |
dc.subject.otherKeywordPlus |
DOSE HALOPERIDOL |
dc.subject.otherKeywordPlus |
CRITICALLY-ILL |
dc.subject.otherKeywordPlus |
DROPERIDOL |
dc.subject.otherKeywordPlus |
PROPHYLAXIS |
dc.subject.otherKeywordPlus |
EFFICACY |
dc.subject.otherKeywordPlus |
INTERVAL |
dc.subject.otherKeywordPlus |
MORPHINE |
dc.subject.otherWOS |
Anesthesiology |